Treatment of breast cancer

The treatment of breast cancer includes the following: Total mastectomy: The whole breast tissue, including nipples, irradiation and partial skin. It applies to patients with large tumours, multi-centre stoves or breast problems. Breastpaste: Only tumors and parts of the surrounding tissue are removed and most breasts are retained. Breastfeeding operations usually require a combination of radiotherapy to reduce the risk of local recurrence. It applies to early breast cancer, with smaller tumours and far from nipples. An armpit lymph scavenger: The purpose is to assess whether or not lymph nodes have been moved and to remove lymph nodes that may have been moved. It can be divided into a full armpit lymph sweep and an outpost lymph close-up. Forward lymph nodes: The lymph nodes of the forward lymph nodes (usually the first to transfer tumour cells) are identified during the operation, and if the lymph nodes of the forward post are not removed, they avoid full lymph nodes cleaning and reduce surgical complications, such as upper leg oedema, abnormal feeling, etc. Radiotherapy III. Chemical treatment IV. Endocrine treatment V. Target-oriented treatment For example, sher2 positive breast cancer patients can receive targeted treatment. Activation mechanisms: Target-oriented drugs can act specifically on specific molecular targets in cancer cells, disrupting the growth signal transmission of cancer cells and thus killing them. Targeting treatment is usually more selective and less toxic than chemotherapy. Therapeutic drug: Ticto-Choto stand alone: a single clone antibodies for HeR2 receptors that can be used for HeR2 positive breast cancer treatment. Usually used in combination with chemotherapy, it can significantly improve the survival of patients. Pato Joo: It is also a single clone antibodies for HeR2 receptors, which are used in combination with Tutu Joo, which further enhances the treatment of HeR2 positive breast cancer. Other target drugs, such as Lapatini, Nadini and others, can be used for the second or third-line treatment of HeR2 positive breast cancer. Immunotherapy: The current application of immunotherapy to breast cancer is directed at patients with triple-negative breast cancer, especially those with high tumour mutation loads (TMB) or microsatellite volatility (MSI-H). Mechanisms of action: Immunocellular recognition and ability to attack cancer cells through activation of the patient ‘ s own immune system. Therapeutic drug: Keytruda: a PD-1 inhibitor which has been approved for use in the treatment of specific types of patients with triple-negative breast cancer